|
Distinct clinical characteristics of young-onset pancreatic cancer patients. |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Travel, Accommodations, Expenses - NanoCarrier; NanoCarrier; NanoCarrier; NanoCarrier |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Consulting or Advisory Role - Bristol-Myers Squibb (Inst); Bristol-Myers Squibb (Inst); Bristol-Myers Squibb (Inst); Bristol-Myers Squibb (Inst) |
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Merck; Merck; Merck; Merck; PledPharma; PledPharma; PledPharma; PledPharma |
|
|
Consulting or Advisory Role - Array BioPharma; Array BioPharma; Array BioPharma; Array BioPharma; Boston Biomedical; Boston Biomedical; Boston Biomedical; Boston Biomedical; Celgene; Celgene; Celgene; Celgene; Genentech/Roche; Genentech/Roche; Genentech/Roche; Genentech/Roche; Guardant Health; Guardant Health; Guardant Health; Guardant Health; Ipsen; Ipsen; Ipsen; Ipsen |
Speakers' Bureau - Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Genentech/Roche; Genentech/Roche; Genentech/Roche; Genentech/Roche; Ipsen; Ipsen; Ipsen; Ipsen |
Research Funding - Agios (Inst); Agios (Inst); Agios (Inst); Agios (Inst); ArQule (Inst); ArQule (Inst); ArQule (Inst); ArQule (Inst); AstraZeneca/MedImmune (Inst); AstraZeneca/MedImmune (Inst); AstraZeneca/MedImmune (Inst); AstraZeneca/MedImmune (Inst); Bristol-Myers Squibb (Inst); Bristol-Myers Squibb (Inst); Bristol-Myers Squibb (Inst); Bristol-Myers Squibb (Inst); CASI Pharmaceuticals (Inst); CASI Pharmaceuticals (Inst); CASI Pharmaceuticals (Inst); CASI Pharmaceuticals (Inst); Celgene (Inst); Celgene (Inst); Celgene (Inst); Celgene (Inst); Five Prime Therapeutics (Inst); Five Prime Therapeutics (Inst); Five Prime Therapeutics (Inst); Five Prime Therapeutics (Inst); Genentech (Inst); Genentech (Inst); Genentech (Inst); Genentech (Inst); ImmuneSensor Therapeutics; ImmuneSensor Therapeutics; ImmuneSensor Therapeutics; ImmuneSensor Therapeutics; MedImmune (Inst); MedImmune (Inst); MedImmune (Inst); MedImmune (Inst); Merck Serono (Inst); Merck Serono (Inst); Merck Serono (Inst); Merck Serono (Inst); Sillajen (Inst); Sillajen (Inst); Sillajen (Inst); Sillajen (Inst); Tolero Pharmaceuticals (Inst); Tolero Pharmaceuticals (Inst); Tolero Pharmaceuticals (Inst); Tolero Pharmaceuticals (Inst) |
|
|
No Relationships to Disclose |